Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Endocrine 1

Conditions

Sarcoma 26Gliosarcoma 22Glioblastoma 21Glioma 16Ependymoma 15Astrocytoma 12Osteosarcoma 11Oligodendroglioma 11Central Nervous System Neoplasms 10Rhabdomyosarcoma 9Medulloblastoma 9Sarcoma, Ewing 7Neuroblastoma 7Glioma, Subependymal 7Brain Neoplasms 7Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroectodermal Tumors, Primitive 6Neoplasm Metastasis 6Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Histiocytosis, Langerhans-Cell 6Carcinosarcoma 6Wilms Tumor 5Liposarcoma 5Hepatoblastoma 5Carcinoma, Transitional Cell 5Sarcoma, Kaposi 4Ovarian Neoplasms 4Meningioma 4

Interventions

Ifosfamide 3Doxorubicin 3Radiotherapy 2Imatinib Mesylate 2Filgrastim 2trebananib 1selurampanel 1selinexor 1saracatinib 1perifosine 1elacestrant 1Trabectedin 1Thalidomide 1Temozolomide 1Sunitinib 1RAD1901 1Postmortem Imaging 1Paclitaxel 1Mass Spectrometry 1Magnetic Resonance Spectroscopy 1Injections 1High-Energy Shock Waves 1Fulvestrant 1Cyproheptadine 1Chromatography, High Pressure Liquid 1Chemotherapy, Adjuvant 1Biopsy 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Endometrial Stromal × Magnetic Resonance Spectroscopy × Sarcoma × Clear all
NCT02150213 2016-12-05

Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492

Novartis

Phase 2 Completed
59 enrolled 6 charts
EndocrineGynecologicSarcoma

Sarcoma, Endometrial Stromal, Adrenocortical Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡